An 81-year-old man with a history of prostate cancer, treated with localized therapy via brachytherapy seeds, presented with right-side flank pain. There was no hematuria and the patient did not have a fever or elevated white count.
CLINICAL HISTORY
An 81-year-old man with a history of prostate cancer, treated with localized therapy via brachytherapy seeds, presented with right-side flank pain. There was no hematuria and the patient did not have a fever or elevated white count.
In 2005, he was treated with ureteroscopy and retrograde pyelography with balloon dilatation and stent insertion for right-side obstruction.
The hydronephrosis resolved, and the patient had been doing well since that time. His past medical history is otherwise unremarkable. The patient’s PSA was normal.
A CT of the abdomen and pelvis was ordered.
FINDINGS
Figure 1: Scout tomogram prior to the CT demonstrates the presence of brachytherapy seeds in the region of the prostate gland and a left hip arthroplasty. No definite opaque calculi are seen projecting over the kidneys or paths of the ureters. Note the single metallic density to the right of and superior to the other cluster of radioactive seeds.
Figure 2: A noncontrast enhanced CT image of the right kidney demonstrates the presence of hydronephrosis (swelling of one kidney due to a backup of urine). No renal calculi are seen. We were able to follow the ureter to the level of the ureterovesical junction (UVJ), and was dilated (not shown).
Figure 3: A noncontrast CT image of the pelvis demonstrates a metallic brachytherapy seed (arrows) lying adjacent to the distal right ureter, superior to and completely separate from the prostate gland. This was a new finding when compared to a prior study (not shown). Incidentally noted is streak artifact from the patient’s hip prosthesis.
DISCUSSION
The patient was scheduled for cystoscopy and right retrograde pyelography/ureteroscopy, with possible balloon dilatation and stent placement.
Dr. Spitzer is associate director of radiology at Montgomery Hospital in Norristown, PA. He can be reached at lspitzer@mont-hosp.com.
FDA Grants Expanded 510(k) Clearance for Xenoview 3T MRI Chest Coil in GE HealthCare MRI Platforms
November 21st 2024Utilized in conjunction with hyperpolarized Xenon-129 for the assessment of lung ventilation, the chest coil can now be employed in the Signa Premier and Discovery MR750 3T MRI systems.
FDA Clears AI-Powered Ultrasound Software for Cardiac Amyloidosis Detection
November 20th 2024The AI-enabled EchoGo® Amyloidosis software for echocardiography has reportedly demonstrated an 84.5 percent sensitivity rate for diagnosing cardiac amyloidosis in heart failure patients 65 years of age and older.
New Study Examines Agreement Between Radiologists and Referring Clinicians on Follow-Up Imaging
November 18th 2024Agreement on follow-up imaging was 41 percent more likely with recommendations by thoracic radiologists and 36 percent less likely on recommendations for follow-up nuclear imaging, according to new research.